Drug Profile
Research programme: bispecific antibody (Novotarg) - Baliopharm AG/University of Tubingen
Alternative Names: Bispecific antibody targeting CD20 and CD95 (Novotarg) for autoimmune diseases and cancer - Baliopharm; Novotarg; Protein therapeutic for immune-mediated inflammatory diseases and cancer - BaliopharmLatest Information Update: 17 Apr 2018
Price :
$50
*
At a glance
- Originator University of Tubingen
- Developer Baliopharm AG
- Class Bispecific antibodies; Proteins
- Mechanism of Action CD20 antigen inhibitors; CD95 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Lymphoma; Multiple sclerosis
Most Recent Events
- 10 Apr 2018 Baliopharm AG has been acquired by Promethera Biosciences
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in Switzerland (Parenteral)
- 28 Feb 2018 No recent reports of development identified for preclinical development in Lymphoma in Switzerland (Parenteral)